Evidence map›Paper›PMID 26713602›Full record

ArticleOncotarget2016

CCL3 promotes angiogenesis by dysregulation of miR-374b/ VEGF-A axis in human osteosarcoma cells.

Yuan-Ya Liao, Hsiao-Chi Tsai, Pei-Yu Chou, Shih-Wei Wang, Hsien-Te Chen, Yu-Min Lin, I-Ping Chiang, Tzu-Ming Chang, Shao-Keh Hsu, Ming-Chih Chou and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 91 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Developing a 3D bone model of osteosarcoma to investigate cancer mechanisms and evaluate treatments.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Promise and Challenges of T Cell Immunotherapy for Osteosarcoma.International journal of molecular sciences · 2023
    Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Yuan-Ya LiaoInstitute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Hsiao-Chi TsaiGraduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan.
Pei-Yu ChouDepartment of Nursing, Hung Kuang University, Taichung, Taiwan.
Shih-Wei WangDepartment of Medicine, Mackay Medical College, New Taipei City, Taiwan.
Hsien-Te ChenDepartment of Orthopedic Surgery, China Medical University Hospital, Taichung, Taiwan.
Yu-Min LinDepartment of Medicine, Chung Shan Medical University, Taichung, Taiwan.
I-Ping ChiangDepartment of Pathology, China Medical University Hospital, Taichung, Taiwan.
Tzu-Ming ChangDepartment of Orthopedic Surgery, Tungs' Taichung Metroharbor Hospital, Taichung, Taiwan.
Shao-Keh HsuDepartment of Orthopedic Surgery, Tungs' Taichung Metroharbor Hospital, Taichung, Taiwan.
Ming-Chih ChouInstitute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Chih-Hsin TangGraduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan.
Yi-Chin FongDepartment of Orthopedic Surgery, China Medical University Hospital, Taichung, Taiwan.
China Medical University · TWChina Medical University Hospital · TWChung Shan Medical University · TWTungs' Taichung MetroHarbor Hospital · TWHungkuang University · TWMackay Medical College · TWTaichung Veterans General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma is the most frequent bone tumor, characterized by a high metastatic potential. However, the crosstalk between chemokine (C-C motif) ligand 3 (CCL3), which facilitates tumor progression and metastasis. Vascular endothelial growth factor-A (VEGF-A), an angiogenesis inducer and a highly specific mitogen for endothelial cells, has not been well explored in human osteosarcoma. Here we demonstrate the correlation of CCL3 and VEGF-A expressions, quantified by immunohistochemistry, with the tumor stage of human osteosarcoma tissues. Furthermore, CCL3 promotes VEGF-A expression in human osteosarcoma cells that subsequently induces human endothelial progenitor cell (EPC) migration and tube formation. Phosphorylation of JNK, ERK, and p38 was found after CCL3 stimulation. In addition, JNK, ERK, and p38 inhibitors also abolished CCL3-induced VEGF-A expression and angiogenesis. We noted that CCL3 reduces the expression of miR-374b and miR-374b mimic by reversing CCL3-promoted VEGF-A expression and angiogenesis in vitro and in vivo. This study shows that CCL3 promotes VEGF-A expression and angiogenesis in human osteosarcoma cells by down-regulating miR-374b expression via JNK, ERK, and p38 signaling pathways. Thus, CCL3 may be a new molecular therapeutic target in osteosarcoma angiogenesis and metastasis.

Indexed as

AnimalsApoptosisBlotting, WesternBone NeoplasmsCell MovementCell ProliferationCells, CulturedChemokine CCL3ChickensChorioallantoic MembraneEndothelial Progenitor CellsHumansImmunoenzyme TechniquesMaleMiceMice, Inbred BALB CCCL3 protein, humanChemokine CCL3MicroRNAsMIRN374 microRNA 374, humanRNA, MessengerRNA, Small InterferingVascular Endothelial Growth Factor AVEGFA protein, humanangiogenesisMAPKmiR-374bosteosarcomaVEGF-A

Identifiers

PMID26713602
PMCPMC4826207
OpenAlexW2212174305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.